MetaSight has developed next generation Metabolomics/Lipidomics technologies for allowing unbiased, high throughput analyses of full metabolic profiles.

The company develops cost-effective diagnostic panels covering multiple disease areas, including oncology, inflammatory, metabolic, neurodegenerative, infectious disease and others.MetaSight employs proprietary cost-effective mass-spectrometry technology combined with deep analytical capabilities, facilitating untargeted biomarker discovery on a population-scale.